DAEWOONG CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,400 KRW | +2.33% |
|
-2.16% | -25.42% |
| 14/05 | Daewoong Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 24/04 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| Sales 2022 | 1,697B 1.23B 102B | Sales 2023 | 1,814B 1.31B 109B | Capitalization | 846B 612M 51.08B |
|---|---|---|---|---|---|
| Net income 2022 | 103B 74.16M 6.19B | Net income 2023 | 153B 110M 9.22B | EV / Sales 2022 | 0.53 x |
| Net Debt 2022 | 58.39B 42.22M 3.52B | Net Debt 2023 | 182B 131M 10.97B | EV / Sales 2023 | 0.57 x |
| P/E ratio 2022 |
8.25
x | P/E ratio 2023 |
5.59
x | Employees | 348 |
| Yield 2022 |
0.49% | Yield 2023 |
0.48% | Free-Float | 31.94% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +2.33% | ||
| 1 week | -2.16% | ||
| 1 month | -6.21% | ||
| 3 months | -23.76% | ||
| 6 months | -25.42% | ||
| Current year | -25.42% |
1 week
15 050.00
16 140.00
1 month
15 050.0017 640.00
Current year
15 050.0027 100.00
1 year
11 460.0027 100.00
3 years
11 460.0048 100.00
5 years
6 470.0086 700.00
10 years
6 470.0086 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jae-Chun Yoon
CEO | Chief Executive Officer | 64 | 01/85/01 |
Chang-Jae Lee
BRD | Director/Board Member | 47 | 01/02/01 |
Woo-Bang Jeon
AUD | Comptroller/Controller/Auditor | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Young-Cheol Kang
BRD | Director/Board Member | 67 | 29/22/29 |
Jae-Chun Yoon
CEO | Chief Executive Officer | 64 | 01/85/01 |
Geon-Haeng Lee
BRD | Director/Board Member | 63 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 114 M€ | +5.50% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/24/28 | 15,400 | +2.33% | 43,514 |
| 27/24/27 | 15,050 | -4.32% | 82,891 |
| 26/24/26 | 15,730 | -0.44% | 38,359 |
| 25/24/25 | 15,800 | -1.00% | 30,684 |
| 24/24/24 | 15,960 | +1.40% | 78,243 |
End-of-day quote Korea S.E., June 28, 2024
More quotes
Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.42% | 457M | |
| +20.70% | 43.77B | |
| +30.16% | 22.83B | |
| +20.33% | 15.56B | |
| +18.68% | 14.34B | |
| +54.86% | 12.96B | |
| -0.05% | 6.79B | |
| -11.72% | 6.41B | |
| -8.87% | 5.73B | |
| +14.65% | 5.69B |
- Stock Market
- Equities
- A003090 Stock
